Dizal to Present Latest Clinical Data at ASH 2026

The Quick Take
Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Reap, Meitu's EveLab Insight, and Pivota Sign MOU to Explore Bringing Agentic Beauty Shopping to Life
The collaboration would connect personalized consumer experiences and the checkout experience with Reap's agentic payments solution HONG KONG, Nov. 5, 2026…
Business
Rheinmetall shares slump 16% after second 2026 outlook cut in Q3 results
Business
UBS downgrades PagSeguro stock rating on rate concerns
Business
